跳至主要内容
临床试验/NCT05881291
NCT05881291已完成4 期

Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement

Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2023年6月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
124
试验地点
1
主要终点
primary endpoint was the area under the curve below baseline MAP (MAP-time integral) during the 15 min after induction

研究概览

简要总结

Aortic valve stenosis is the most common debilitating valvular heart lesion in old patients. Transcatheter aortic valve replacement (TAVR) is an emergent technique for high-risk patients with aortic stenosis. In recent times, treatment has expanded to also include low- and intermediate-risk individuals. General anesthesia offers many advantages, mainly regarding the possibility of an early diagnosis and treatment of possible complications through the use of transesophageal echocardiography. Propofol is the most used sedative-hypnotic agent for the induction and maintenance of general anesthesia. However, adverse events such as hypotension, and bradycardia are associated with propofol sedation. Ciprofol is a novel anesthetic/sedative agent similar to propofol, with an equivalent efficacy ratio to propofol of 1/4 to 1/5. Ciprofol has properties of fast onset of action, rapid recovery, reduced injection pain and stable cardiorespiratory function, making it a promising alternative to propofol. The aim of this study is to explore the safety and efficacy of ciprofol when used for general anesthesia in patients undergoing transcatheter aortic valve replacement compared to propofol.

详细描述

After assessing patient eligibility, they were randomly assigned to two equally sized groups.Patients in this study were fasted for a minimum of 8 h without premedication.

Following arrival in the operating room, patients were monitored with electrocardiography, respiratory rate, pulse oximetry, bispectral index (BIS), cerebral oxygen saturation,and continuous invasive arterial blood pressure. Induction of anesthesia: group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s; group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s.

When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.

Endotracheal intubation was performed when alfentanil and rocuronium had fully worked, and the BIS value was <50. A ventilator was then connected for mechanical ventilation using the following parameters: VT 6-8 ml/kg, RR 12-20 times/min, the inspiratory-to-expiratory ratio of 1:2, oxygen flowed 2 L/min, and maintaining PETCO2 at 35-45 mmHg (1 mmHg=0.133 kPa).

Maintenance of anesthesia:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients planned for transfemoral transcatheter aortic valve replacement
  • expected duration of surgery ≥ 1 and ≤ 3h
  • patients undergoing general anesthesia
  • no gender limit,age≥60 years,≤85 years
  • BMI ≥18 and ≤30kg/m2
  • ASA physical status 3~4
  • be able to understand the procedures and methods of the trial and voluntarily sign the informed consent form

排除标准

  • predicted presence of difficult airway or previous history of difficult airway
  • allergic to eggs, soy products, propofol, and opioids and their antidotes
  • patients with shock or hypotension that is difficult to correct with vasopressor
  • patients with mental, nervous system diseases, long-term use of sedatives or antidepressants
  • HB < 10.0 g/dL (100 g/L)
  • patients with previous long-term use of sedative and analgesic drugs
  • patients with severe heart,lung,liver and kidney disease
  • not suitable for participation in this study as assessed by the investigator

研究组 & 干预措施

group propofol

Active Comparator

Patients receive propofol for general anesthesia

干预措施: propofol (Drug)

group ciprofol

Experimental

Patients receive ciprofol for general anesthesia

干预措施: ciprofol (Drug)

结局指标

主要结局

primary endpoint was the area under the curve below baseline MAP (MAP-time integral) during the 15 min after induction

时间窗: from the start of induction of anesthesia to 15 minutes after induction of anesthesia

the area under the baseline MAP over the first 15 min after induction, called the MAP-time integral

次要结局

  • Incidence of hypotension(within 15 minutes after induction of anesthesia)
  • Incidence of bradycardia(within 15 minutes after induction of anesthesia)
  • dose of vasopressor used within 15 minutes after induction of anesthesia and vasopressor drugs used during surgery(during the surgery)
  • Incidence of injection pain(during the induction of anesthesia procedure)
  • Incidence of postoperative nausea and vomiting(1 day (during anesthesia awakening))
  • Quality of life and disease recovery (QoR-15) score on postoperative day 1(1 day after surgery)
  • changes of IL-6 before and one first day after surgery(immediately before surgery and one first day after surgery)
  • changes of CK-MB and cTnT before and one first day after surgery(immediately before surgery and one first day after surgery)
  • Composite Clinical Endpoint at 1 Year (Extended Follow-up Analysis)(1 year post-procedure)

研究者

发起方
Second Affiliated Hospital, School of Medicine, Zhejiang University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验